Overview of Managers' Transactions at Orion Corporation
Orion Corporation is committed to transparency and accountability in its operations. Recently, a disclosure was made concerning share transactions involving Eija Ronkainen, a notable member of the company's Board. This transaction is governed by the Market Abuse Regulation (EU) No 596/2014.
Details of the Disclosure
The notification regarding the transaction identified Eija Ronkainen as a key figure involved in the transaction of shares. Eija serves as a Member of the Board and also holds the position of Deputy member within the organization.
Transaction Summary
The transaction took place on April 30, with information detailing the nature and scope of shares involved. A total of 415 shares were received as part of a share-based incentive scheme. The unit price for this transaction was recorded as 0 EUR, suggesting the shares might have been allocated without direct cost to the recipient, which is common in many incentive programs.
The aggregated data from this transaction states a volume of 415 shares at a volume-weighted average price of 0 EUR, emphasizing the incentive nature of the awards provided to the managerial staff.
About Orion Corporation
Founded over a century ago, Orion Corporation has established itself as a pioneering force in the pharmaceutical industry. The company not only develops and markets human and veterinary pharmaceuticals but also produces active pharmaceutical ingredients. It is noteworthy that Orion has a rich portfolio that includes both proprietary and generic medications, along with consumer health products.
Core Focus Areas
Orion’s research and development efforts primarily focus on oncology and pain management, where they work on innovative solutions to enhance patient care. Their proprietary products are utilized in treating various serious health issues, including cancer and neurological disorders.
Financial Performance and Workforce
In a recent financial overview, Orion Corporation reported net sales of EUR 1,542 million. The company operates on a global scale, with a workforce of approximately 3,700 dedicated professionals committed to advancing health and well-being.
Commitment to Well-being
Orion's mission revolves around enhancing the quality of life through its extensive range of health solutions, exemplifying a long-established tradition of contributing significantly to global health. Investors can find Orion's shares traded on the Nasdaq Helsinki under the ticker Helsinki:ORNBV.
Contact Information:
Publisher: Orion Corporation
Communications
Address: Orionintie 1A, FI-02200 Espoo, Finland
Frequently Asked Questions
What is the nature of the transaction undertaken by Eija Ronkainen?
The transaction involved the receipt of shares as part of a share-based incentive program recognized under the Market Abuse Regulation.
What is Orion Corporation known for?
Orion Corporation is a well-known Nordic pharmaceutical company that focuses on developing human and veterinary pharmaceuticals.
What were the financial highlights for Orion in the previous year?
In the last fiscal year, Orion reported net sales of EUR 1,542 million.
How many employees does Orion Corporation have?
Orion employs about 3,700 professionals worldwide who are dedicated to improving health and well-being.
Where are Orion Corporation's shares listed?
Shares of Orion Corporation are listed on the Nasdaq Helsinki market, under the ticker Helsinki:ORNBV.
